Raymond James Financial’s Cidara Therapeutics CDTX Stock Holding History

Raymond James Financial’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,268	Closed	-$501K	–	5321
2025 Q4	$501K	Sell	2,268 -1,792	-44%	-$290K	﹤0.01%	4265
2025 Q3	$389K	Buy	4,060 +1,066	+36%	+$68K	﹤0.01%	4267
2025 Q2	$146K	Buy	+2,994	New	+$72K	﹤0.01%	4674

Raymond James Financial's CDTX Position: Q1 2026 in Review

Raymond James Financial sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 2,268 shares — an estimated $501K sold.

Raymond James Financial first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $501K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Raymond James Financial reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Raymond James Financial sold 2,268 Cidara Therapeutics shares in Q1 2026, an estimated $501K.
Raymond James Financial first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Raymond James Financial's Cidara Therapeutics position peaked at $501K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.